Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care
for People with Parkinson’s disease (PWP).
1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s
Disease: probable diagnosis.
2. Willingness to undergo genetic testing, and choose to be informed of genetic testing
results for Glucosylceramidase Beta (GBA), LRRK2 and 5 additional PD related genes
(SNCA, VPS35, PRKN, PINK-1, PARK7).
3. Capacity to give full informed consent in writing, and have read and signed the
informed consent forms (ICFs) based on clinician’s determination.
4. Able to perform study activities (including completion of either online, in-person or
5. Individuals must speak and understand the English language.
1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy,
progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome),
including that due to medications, metabolic disorders, encephalitis, cerebrovascular
disease, or normal pressure hydrocephalus.
2. Individuals who have received a blood transfusion within the past 3 months.
3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.
4. Individuals who have had a bone marrow transplant within the past 5 years.
- University of California San Diego (UCSD), La Jolla, California, United States, 92093